Congress Program
Prof. Dr. Dirk Schadendorf, Germany I Congress Chair
Medical University Graz, Austria
Astrid Coste1,2, Brian Koster3, Jean-François Doré2, Philippe Autier4
1Département Prévention Cancer Environment, Centre Léon Bérard, France
2Défense, Santé, Environnement, INSERM UMR1296 Radiations, France
3Cancer Prevention & Information, Danish Cancer Society, Denmark
4Research, International Prevention Research Institute (i-PRI), France
Medical Chambers Kensington, UK
University of Versailles-SQY & University Paris-Saclay, France
Amsterdam UMC, Netherlands
Gustave Roussy Comprehensive Cancer Center, France
Leiden University Medical Center, Netherlands
University Hospital Essen, Germany
Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland
University Hospital Bonn, Germany
Charité University Medicine Berlin, Germany
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Alexander Eggermont1,2
1Cancer Medicine, University Medical Center Utrecht and Prinses Maxima Center, Netherlands
2Board, Comprehensice Cancer Center Munich of the TUM and LMU Universities, Munich, Germany
Adjuvant therapy in melanoma can be devided in the Old Era (Interferon-alpha) and the New Era (ipilimumab , nivolumab, pembrolizumab for all stage III patients regardless of BRAF status, and the option of dabrafenbib+trametinib combination for BRAFmutant patients)
In general : what works in advanced melanoma also works in the adjuvant setting
An overview of the adjuvant ipilimumab, nivolumab, pembrolizumab and dabrafenib + trametinib phase 3 trials will be presented. Moreover the success of adjuvant ipilimumab+nivolumab in resected stage IV and the failure of a different schedule of ipilimumab+nivolumab in stage IIIB/IV.
The recent data of adjuvant pembrolizumab and nivolumab in stage IIB/IIC will be presented and the smaller absolute benefits of adjuvant therapy in lower stages of melanoma.
Biomarker approches to identify those patients with the highest risks will be discussed and their potential value in the very big patient populations stages IB-IIA and IIB/C
Simple rescheduling pembrolizumab by administering the first 3 doses before the lymphnode dissection in patients with macroscopic stage III melanoma (the SWOG1801 Trial) provide a new best practice because of a further 42% reduction of relapses compared to standard adjuvant 18 doses of pembrolizumab. This observation will be highlighted and provides the bridge to the current revolution: NEO-Adjuvant immunotherapy.
University Hospital Würzburg, Germany
University Medical Center Hamburg-Eppendorf (UKE), Germany
Aix-Marseille University, France
KU LEUVEN, Belgium
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Netherlands
Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland
Helios Hospital Krefeld, Germany
Philippe Autier1
Research, International Prevention Research Institute (i-PRI), France
Philippe Autier1
Research, International Prevention Research Institute, France
Universitair Ziekenhuis Brussel, Belgium
University Hospital Essen, Germany Congress Chair
University Catholic of Louvain, Belgium
Prof. Dr. Dirk Schadendorf, Germany I Congress Chair